Clinical Trial Update: A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

OTP-01, a dual PD-1/VEGFR2 antibody developed by Ottimo Pharma, is being studied in Phase 1/2 for advanced solid tumors with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• OTP-01

Snippet

Sponsor: Ottimo Pharma Limited | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING